Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0018133 (
graft-versus-host disease
)
18,032
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Considering the merit and demerit of
GVHD
in leukemia patients following allogeneic BMT, our strategies for
GVHD
are as follows; (1) a mild prevention, (2) a treatment to control the severity, if occurred, and (3) an induction of
GVHD
in recipients who did not develop
GVHD
. We reported the results of recent trials in prevention, treatment and induction of
GVHD
. For the prevention, T cells were depleted from bone marrow cells in 11 recipients with the results of graft failure in 5 and death in 9. The data from IBMTR were similar to our data. For the treatment, new drugs, 15-
Deoxyspergualin
. Mizoribine and anti-human lymphocyte globulin were introduced with compromising outcomes and mild adverse effects. For the induction, Ubenimex, an immunostimulator, was administered to recipients who did not develop
GVHD
until 30 days after BMT. The interim data suggests that Ubenimex may induce chronic
GVHD
and suppress the relapse of leukemia. We experienced the sudden onset of
GVHD
during the tapering of immunosuppressants in two recipients, who were found to have arbitrarily discontinued them. The interruption of drugs for the prevention of
GVHD
may cause the induction of
GVHD
.
...
PMID:[Control of graft-vs-host disease]. 239 9
